A role for TET2 in parathyroid carcinoma

Endocrine-Related Cancer

Volumn 24, Issue 7, 2017, Pages 329-338

  Barazeghi, Elham ^a   Gill, Anthony J ^b   Sidhu, Stan ^c,d   Norlen, Olov ^a,c,d   Dina, Roberto ^e   Palazzo, F Fausto ^e   Hellman, Per ^a   Stalberg, Peter ^a   Westin, Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

5 hydroxymethylcytosine; Parathyroid carcinoma; Primary hyperparathyroidism; Promoter hypermethylation; TET2; Tumor suppressor

Indexed keywords

BISULFITE; DECITABINE; PROTEIN; TET2 PROTEIN; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; THYROIDECTOMY; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; CELL MOTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PARATHYROID TUMOR; PATHOLOGY;

5-METHYLCYTOSINE; CELL GROWTH PROCESSES; CELL MOVEMENT; DNA METHYLATION; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; PARATHYROID NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRANSFECTION;

EID: 85037077860     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-17-0009     Document Type: Article

References (38)

1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, et at. 2009 Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114 144-147. (doi:10.1182/blood-2009-03-210039)
2. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS & Sunyaev SR 2010 A method and server for predicting damaging missense mutations. Nature Methods 7 248-249. (doi:10.1038/nmeth0410-248)
3. Barazeghi E, Gill AJ, Sidhu S, Norlen O, Dina R, Palazzo FF, Hellman P, Stalberg P & Westin G 2016 S-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma. Clinical Epigenetics 8 31. (doi:10.1186/sl3148-016-0197-2)
4. Bjorklund P, Akerstrom G & Westin G 2007 Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1. Biochemical and Biophysical Research Communications 352 532-536. (doi:10.1016/j.bbrc.2006.11.056)
5. Calabrese R, Valentini E, Ciccarone F, Guastafierro T, Bacalini MG, Ricigliano VA, Zampieri M, Annibali V, Mechelli R, Franceschi C, et al. 2014 TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells. Biochimica et Biophysica Acta 1842 1130-1136. (doi:10.1016/j.bbadis.2014.04.010)
6. Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, Torregrossa L, Basolo F, Pelizzo MR, Rugge M, et al. 2013 CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocrine Connections 2 186-195. (doi:10.1530/EC-13-0046)
7. Chim CS, Wan TS, Fung TK & Wong KF 2010 Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms, /ournal of Clinical Pathology 63 942-946. (doi:10.1136/jcp.2010.080218)
8. DeLellis RA, Mazzaglia P & Mangray S 2008 Primary hyperparathyroidism a current perspective. Archives of Pathology and Laboratory Medicine 132 1251-1262. (doi: 10.1043/1543-2165(2008)132(1251:PHACP)2.0.CO;2)
9. Gill AJ 2014 Understanding the genetic basis of parathyroid carcinoma. Endocrine Pathology 25 30-34. (doi:10.1007/sl2022-013-9294-3)
10. Guarnieri V, Battista C, Muscarella LA, Bisceglia VI, de Martino D, Baorda F, Maiello E, D'Agruma L, Chiodini 1, Clemente C, et al. 2012 CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cellular Oncology 35 411-422. (doi:10.1007/sl3402-012-0100-x)
11. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, lacobuzio-Donahue C, Nelson WG, et al. 2011 Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget2 627-637. (doi:10.18632/oncotarget.316)
12. Huang Y & Rao A 2014 Connections between TET proteins and aberrant DNA modification in cancer. Trends in Genetics 30 464-474. (doi:10.1016/j.tig.2014.07.005)
13. Iacobonc M, Ruffolo C, Lumachi F & Favia G 2005 Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbeck's Archives of Surgery'390 385-390. (doi:10.1007/s00423-005-0555-6)
14. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC & Zhang Y 2010 Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466 1129-1133. (doi: 10.1038/nature09303)
15. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA & Maciejewski JP 2009 Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood WS 6403-6410. (doi: 10.1182/blood-2009-02-205690)
16. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. 2010 Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466 869-873. (doi:10.1038/nature09208)
17. Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M & Ohgaki H 2011 TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations, /ournal of Clinical Pathology 64 850-852. (doi:10.1136/jclinpath-2011-200133)
18. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al. 2010 Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468 839-843. (doi:10.1038/nature09586)
19. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H & Koike K 2012 Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Science Wi 670-676. (doi:10.1111/j.l349-7006.2012.02213.x)
20. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria A, Ware JS, Hill AJ, Cummings BB, et al. 2016 Analysis of protein-coding genetic variation in 60, 706 humans. Nature 536 285-291. (doi:10.1038/naturel9057)
21. Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, etah 2016 Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Scientific Reports 6 26591. (doi:10.1038/srep26591)
22. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Ian L, Hu Y, Zhan Q, et al . 2012 Loss of 5-hydroxymethyIcytosine is an epigenetic hallmark of melanoma. Cell 150 1135-1146. (doi:10.1016/j.cell.2012.07.033)
23. Musialik E, Bujko M, Wypych A, Matysiak M & Siedlecki JA 2014 TET2 promoter DNA methylation and expression analysis in pediatric B-cell acute lymphoblastic leukemia. Hematology Reports 6 5333. (doi:10.4081/hr.2014.5333)
24. Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, etal. 2016 TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene 36 2172-2183. (doi:10.1038/onc.2016.376)
25. Pei YF, Tao R, Li JF. Su LP, Yu BQ, Wu XY, Yan M, Gu QL, Zhu ZG & Liu BY 2016 TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression. Oncotarget 7 31322-31335. (doi:10.18632/oncotarget.8900)
26. Rasmussen KD & Helin K 2016 Role of TET enzymes in DNA methylation, development, and cancer. Genes and Development30 733-750. (doi:10.1101/gad.276568.115)
27. Rasmussen KD, Jia G, Johansen JV, Pedersen MI, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J & Helin K 2015 Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes ami Development 29 910-922. (doi:10.1101/gad.260174.115)
28. Scourzic L, Mouly E & Bernard OA 2015 TET proteins and the control of cytosine demethylation in cancer. Genome Medicine 7 9. (doi:10.1186/sl3073-015-0134-6)
29. Sharretts JM & Simonds WF 2010 Clinical and molecular genetics of parathyroid neoplasms. Best Practice and Research: Clinical Endocrinology and Metabolism 24 491-502. (doi:10.1016/j. beem.2010.01.003)
30. Svedlund J, Auren M, Sundstrom M, Dralle H, Akerstrom G, Bjorklund P & Westin G 2010 Aberrant WNT/beta-catenin signaling in parathyroid carcinoma. Molecular Cancer 9 294. (doi:10.1186/1476-4598-9-294)
31. Svedlund J, Koskinen Edblom S, Marquez VE, Akerstrom G, Bjorklund P & Westin G 2012 Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification. Journal of Clinical Endocrinology and Metabolism 97 E1307-E1315. (doi:10.1210/jc.2011-3136)
32. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer I.M, Liu DR, Aravind L, et ah 2009 Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 930-935. (doi:10.1126/ science.1170116)
33. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, etal. 2004 Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clinical Cancer Research 10 6629-6637. (doi:10.1158/1078-0432.CCR-04-0493)
34. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, etal. 2012 Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26 934-942. (doi:10.1038/leu.2011.326)
35. Westin G 2016 Molecular genetics and epigenetics of nonfamilial (sporadic) parathyroid tumours. Journal of Internal Medicine 280 551-558. (doi:10.1111/joim.l2458)
36. Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, et at. 2015 TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Research 75 2833-2843. (doi:10.1158/0008-5472.CAN-14-0739)
37. Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D, Poon SL, et al. 2015 Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. Journal of Clinical Endocrinology and Metabolism 100 E360-E364. (doi:10.1210/ jc.2014-3238)
38. Zhang J, Yang C, Wang C, Liu D, Lao G, Liang Y, Sun K, Luo H, Tan Q, Ren M, etal. 2016 AGE-induced keratinocyte MMP-9 expression is linked to TET2-mediated CpG demethylation. Wound Repair and Regeneration 24 489-500. (doi: 10.1111/wrr. 12426)